Literature DB >> 2530274

IL-1 induces rapid phosphorylation of the IL-1 receptor.

B Gallis1, K S Prickett, J Jackson, J Slack, K Schooley, J E Sims, S K Dower.   

Abstract

The IL-1R on murine T cells is a Mr = 80,000 plasma membrane glycoprotein. cDNA cloning and transfection experiments have shown that this is an integral membrane protein, which binds both IL-1 alpha and IL-1 beta and transduces the IL-1 signal. A mAb, RM-5, which binds an epitope on the receptor which is distinct from the IL-1 binding site has been produced in rats. RM-5 has been used to immunoprecipitate the IL-1R from 32P-orthophosphate labeled CHO cells which express approximately 100,000 functional, murine rIL-1R/cell. Phosphorylation of the receptor was observed as early as 1 min after the addition of IL-1 and continued for periods of up to 30 min. Phosphorylation increases as the concentration of IL-1 increases from 10(-13) to 10(-8) M. Potassium hydroxide hydrolysis of the phosphorylated IL-1R shows that more than 90% of the phosphate is incorporated into serine or threonine. Thus, one of the earliest events after IL-1 binding to the IL-1R is activation of a serine/threonine protein kinase and phosphorylation of the IL-1R itself.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530274

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Pathophysiologic effect of interleukin-1b in the rabbit retina.

Authors:  J A Martiney; M Litwak; J W Berman; J C Arezzo; C F Brosnan
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.

Authors:  Alexander M Owyang; Hassan Issafras; John Corbin; Kiran Ahluwalia; Paul Larsen; Elizabeth Pongo; Masahisa Handa; Arnold H Horwitz; Marina K Roell; Mary Haak-Frendscho; Linda Masat
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

3.  Cytosolic domain of the type I interleukin-1 receptor spontaneously recruits signaling molecules to activate a proinflammatory gene.

Authors:  R Singh; S Huang; T Guth; M Konieczkowski; J R Sedor
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 4.  Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.

Authors:  R R Bartlett; M Dimitrijevic; T Mattar; T Zielinski; T Germann; E Rüde; G H Thoenes; C C Küchle; H U Schorlemmer; E Bremer
Journal:  Agents Actions       Date:  1991-01

5.  Evidence that interleukin-1 and phorbol esters activate NF-kappa B by different pathways: role of protein kinase C.

Authors:  K Bomsztyk; J W Rooney; T Iwasaki; N A Rachie; S K Dower; C H Sibley
Journal:  Cell Regul       Date:  1991-04

Review 6.  Effects of leflunomide on immune responses and models of inflammation.

Authors:  R R Bartlett; H Anagnostopulos; T Zielinski; T Mattar; R Schleyerbach
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression.

Authors:  K Ye; K C Koch; B D Clark; C A Dinarello
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

8.  Interleukin 1 beta induces rapid phosphorylation and redistribution of talin: a possible mechanism for modulation of fibroblast focal adhesion.

Authors:  E E Qwarnström; S A MacFarlane; R C Page; S K Dower
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Ligand-induced desensitization of interleukin 1 receptor-initiated intracellular signaling events in T helper lymphocytes.

Authors:  D J McKean; C Huntoon; M Bell
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  Understanding the dendritic cell lineage through a study of cytokine receptors.

Authors:  E Kämpgen; F Koch; C Heufler; A Eggert; L L Gill; S Gillis; S K Dower; N Romani; G Schuler
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.